Literature DB >> 15257048

Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type (ATTR Val30Met) patients.

Rolf Hörnsten1, Urban Wiklund, Bert-Ove Olofsson, Steen M Jensen, Ole B Suhr.   

Abstract

BACKGROUND: Orthotopic liver transplantation (OLT) is today the only available treatment to halt the progress of familial amyloidotic polyneuropathy (FAP). Because heart arrhythmia and conduction disturbances are well-known manifestations of FAP, the aim of this study was to investigate the occurrence and development of heart conduction and rhythm disturbances in Swedish FAP patients who underwent liver transplantation.
METHODS: Ambulatory 24-hour electrocardiography (ECG) recordings (Holter-ECGs) were available from 30 patients, who had been investigated before and reexamined after OLT. RESULTS.: The number of patients with abnormalities on their ECG recordings increased after OLT. Four patients developed serious arrhythmia after transplantation that necessitated the insertion of a pacemaker 40 months or longer after OLT.
CONCLUSIONS: The development of cardiac conduction disturbances and arrhythmias appear not to be halted by liver transplantation, indicating that the physician should be aware of the potential risk for FAP patients receiving transplants to develop fatal arrhythmia. The follow-up after liver transplantation should include Holter-ECG recordings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15257048     DOI: 10.1097/01.tp.0000133517.20972.27

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

Review 1.  The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.

Authors:  Steven M Johnson; Stephen Connelly; Colleen Fearns; Evan T Powers; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2012-01-05       Impact factor: 5.469

2.  Pacemaker implantation in familial amyloid polyneuropathy: when and for whom?

Authors:  James Milner; Rafaela Nicolau Teixeira; Ana Vera Marinho; Nuno Silva; Suzana Calretas; José Ferrão; Emanuel Furtado; Maria João Telo; Miguel Ventura; João Cristóvão; Luís Elvas; Guilherme Mariano Pêgo; Natália António
Journal:  J Interv Card Electrophysiol       Date:  2019-03-09       Impact factor: 1.900

Review 3.  CRISPR/Cas9: at the cutting edge of hepatology.

Authors:  Francis P Pankowicz; Kelsey E Jarrett; William R Lagor; Karl-Dimiter Bissig
Journal:  Gut       Date:  2017-05-09       Impact factor: 23.059

4.  Manifestations of transthyretin-related familial amyloidotic polyneuropathy: long-term follow-up of Japanese patients after liver transplantation.

Authors:  Yuki Ohya; Sadahisa Okamoto; Masayoshi Tasaki; Mitsuharu Ueda; Hirofumi Jono; Konen Obayashi; Kazuhisa Takeda; Hideaki Okajima; Katsuhiro Asonuma; Ryuhei Hara; Hidenobu Tanihara; Yukio Ando; Yukihiro Inomata
Journal:  Surg Today       Date:  2011-08-26       Impact factor: 2.549

5.  Abnormal heart rate variability and subtle atrial arrhythmia in patients with familial amyloidotic polyneuropathy.

Authors:  Urban Wiklund; Rolf Hörnsten; Marcus Karlsson; Ole B Suhr; Steen M Jensen
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-07       Impact factor: 1.468

6.  Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis.

Authors:  Thibaud Damy; Daniel P Judge; Arnt V Kristen; Karine Berthet; Huihua Li; Janske Aarts
Journal:  J Cardiovasc Transl Res       Date:  2015-03-06       Impact factor: 4.132

7.  Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis.

Authors:  Ernst Hund
Journal:  Appl Clin Genet       Date:  2012-06-18

8.  Green tea halts progression of cardiac transthyretin amyloidosis: an observational report.

Authors:  Arnt V Kristen; Stephanie Lehrke; Sebastian Buss; Derliz Mereles; Henning Steen; Philipp Ehlermann; Stefan Hardt; Evangelos Giannitsis; Rupert Schreiner; Uwe Haberkorn; Philipp A Schnabel; Reinhold P Linke; Christoph Röcken; Erich E Wanker; Thomas J Dengler; Klaus Altland; Hugo A Katus
Journal:  Clin Res Cardiol       Date:  2012-05-15       Impact factor: 5.460

9.  Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.

Authors:  Teresa Coelho; Luis F Maia; Ana Martins da Silva; Márcia W Cruz; Violaine Planté-Bordeneuve; Ole B Suhr; Isabel Conceiçao; Hartmut H-J Schmidt; Pedro Trigo; Jeffery W Kelly; Richard Labaudinière; Jason Chan; Jeff Packman; Donna R Grogan
Journal:  J Neurol       Date:  2013-08-22       Impact factor: 4.849

Review 10.  Recent advances in transthyretin amyloidosis therapy.

Authors:  Mitsuharu Ueda; Yukio Ando
Journal:  Transl Neurodegener       Date:  2014-09-13       Impact factor: 8.014

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.